NEW YORK – Norwegian cardiovascular testing firm CardiNor announced on Monday an exclusive deal with IBL-America to sell the CardiNor Secretoneurin ELISA test in the US.
Financial and other terms of the agreement were not disclosed.
The deal will initially target research institutes, clinical research organizations, and pharmaceutical firms, creating a commercialization pathway for the test following regulatory clearance in the US, CardiNor said.
According to the Oslo, Norway-based company, secretoneurin is the only biomarker associated with the biological processes related to heart cell calcium involved in a crucial mechanism in the regulation of arrhythmia. CardiNor added that secretoneurin has been called the "missing link biomarker" in heart disease risk assessment.
"Cardiovascular disease research is a key market for IBL-America and CardiNor's Secretoneurin ELISA test is an excellent addition to our portfolio," IBL-America President and CEO Mark Kowal said in a statement. Based in Minneapolis, the firm provides laboratory reagent assays to the life science space.